Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its ...

After rejecting a previous takeover offer from Future Pak, Vanda Pharmaceuticals is now fielding another acquisition proposal ...

AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily ...

Structure Therapeutics is offering over nine million shares on the heels of mid-stage data for its oral GLP-1 receptor ...

Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, ...

Recent M&A activity indicates a potential resurgence in the appetites of larger companies for psychiatric drug development, ...

Securing top talent in research and development and manufacturing will remain challenging for life sciences companies in 2024 ...

BMS presented late-stage results on Tuesday at the ASCO annual meeting which showed the combination of Opdivo and Yervoy ...

While NK cell therapies can potentially avoid the serious side effects sometimes seen with CAR T cell therapies, experts say ...

With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for ...

Experts say approval of Lykos Therapeutics’ MDMA capsules for post-traumatic stress disorder would open the door to further ...

As evidenced by this week’s buyouts by J&J and Merck, Big Pharma appears to have found a sweet spot favoring smaller deals ...